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Abstract 
To determine whether stress-evoked release of endogenous opioids might account for 
hypoalgesia in major depressive disorder (MDD), the µ-opioid antagonist naltrexone (50 
mg) or placebo was administered double-blind to 24 participants with MDD and to 31 
non-depressed controls. Eighty minutes later participants completed a painful foot cold 
pressor test and, after a 5-minute interval, began a 25-minute arithmetic task interspersed 
with painful electric shocks. Ten minutes later participants completed a second cold 
pressor test. Negative affect was greater in participants with MDD than in non-depressed 
controls throughout the experiment, and increased significantly in both groups during 
mental arithmetic. Before the math task, naltrexone unmasked direct linear relationships 
between severity of depression, negative affect while resting quietly, and cold-induced 
pain in participants with MDD. In contrast, facilitatory effects of naltrexone on cold- and 
shock-induced pain were greatest in controls with the lowest depression scores. 
Naltrexone strengthened the relationship between negative affect and shock-induced pain 
during the math task, particularly in the depressed group, and heightened anxiety in both 
groups toward the end of the task. Thus, µ-opioid activity apparently masked a positive 
association between negative affect and pain in the most distressed participants. These 
findings suggest that psychological distress inhibits pain via stress-evoked release of 
opioid peptides in severe cases of MDD. In addition, tonic endogenous opioid 
neurotransmission could inhibit depressive symptoms and pain in people with low 
depression scores. 
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Introduction 
The incidence of major depressive disorder (MDD) ranges between 30-54% in clinic-
based chronic pain patients [4], whereas only about 17% of the general population meet 
the diagnostic criteria for MDD during their lifetime [8]. In fact, depression is more 
common in chronic pain patients than in most other chronic medical conditions [4, 19]. 
While the discomfort, distress, and psychosocial consequences of being in chronic pain 
undoubtedly promote depression [42], a prior history of depression also heightens 
vulnerability to chronic pain [31, 45]. Among other possibilities, this might entail 
neurochemical disturbances (e.g., in serotonin, noradrenaline or opioid neurotransmitters) 
in affective and pain modulation pathways within the central nervous system. 
Patients with MDD rate the intensity of post-operative pain and other painful clinical 
conditions higher than controls [32, 34]. Surprisingly, however, depressed patients are 
less sensitive than controls to pain induced by standard laboratory stimuli such as contact 
heat or electrical stimulation [13-15, 33]. The mechanism of this hypoalgesia is uncertain, 
but could involve stress-induced hypersecretion of beta-endorphins in the bloodstream [5, 
12, 22] or, alternatively, heightened activity in cortical or subcortical pathways 
responsible for stress-induced analgesia [37]. At the cortical level, μ-opioid receptor 
activity decreases in the rostral anterior cingulate cortex in non-depressed women during 
induction of sustained sadness but increases in the left inferior temporal cortex of women 
with MDD, presumably in an effort to suppress emotional responses [30]. At the 
subcortical level, decreased bioavailability of μ-opioid receptors in the posterior thalamus 
of MDD patients is associated with raised plasma corticotropin and cortisol levels, both 
markers of activity in the hypothalamic-pituitary-adrenal axis [30]. The decreased µ-
opioid receptor bioavailability is thought to be due to their occupation by opioid   4 
neurotransmitters or to receptor down-regulation. Such mechanisms might explain why 
morphine fails to suppress cortisol secretion in MDD [49]. 
   The aim of the present study was to investigate the effects of µ-opioid receptor 
blockade and psychological stress on sensitivity to pain in people with MDD. In a 
previous study that involved non-depressed participants, the μ-opioid receptor antagonist 
naltrexone intensified cold-induced pain after stressful mental arithmetic in the most 
discouraged cases [20], implying that discouragement triggers opioid analgesia [3]. As 
discouragement (presenting as a sense of helplessness or hopelessness) is one of the key 
features of depression [24], it was hypothesised that naltrexone would intensify pain more 
readily in participants diagnosed with MDD than in non-depressed controls. This would 
support the view that the opioid system is over-active in MDD. 
Method 
Participants 
The study was advertised in local newspapers and on radio, and fliers were 
distributed in waiting rooms of general practitioners, psychologists and psychiatrists. 
Respondents were interviewed over the telephone to screen for inclusion and exclusion 
criteria, and the Structured Clinical Interview for DSM-IV Axis I Disorders – Clinician 
Version [18] was administered to establish the diagnosis of MDD. Eleven men and 13 
women aged between 17 and 57 years met the criteria for MDD. Another 14 men and 17 
women aged between 18 and 57 years who had no personal or family history of 
psychiatric illness were recruited as controls. Depressed participants reported 
significantly higher levels of anxiety, stress and depression than non-depressed controls 
on the State-Trait Anxiety Inventory, Form Y (STAI) [44], Depression, Anxiety, and 
Stress Scales (DASS) [36], and the Beck Depression Inventory II (BDI) [6] (Table 1). In   5 
comparison to the general adult population, controls reported lower than average levels of 
state anxiety (women 39
th mean percentile rank; men 44
th mean percentile rank) and trait 
anxiety (women 42
nd mean percentile rank; men 43
rd mean percentile rank), and levels of 
depression and stress were within the normal range. Conversely, depressed participants 
reported moderate to severe symptoms of state and trait anxiety, matching levels in the 
top 2-5% of the general population [44]. All participants reported that they were in good 
health. 
Exclusion criteria included psychotic disorders, alcohol and/or other substance 
use disorders, benzodiazepines, DSM-IV Axis II disorders, cigarette smoking, chronic 
pain conditions or headache (all identified during the structured clinical telephone 
interview). In addition, respondents currently taking hypericum perforatum (St John’s 
Wort) or antidepressant medication were excluded. Five participants had taken selective 
serotonin reuptake inhibitors in the past but had ceased taking these drugs five weeks to 
six months (median four months) before their recruitment into the study. Participants 
reduced their alcohol intake for one week prior to testing, and refrained from alcoholic or 
caffeinated beverages for 12 hours before the experiment. They also refrained from food 
for two hours before the experiment. None of the participants used opiates regularly or 
had ever taken naltrexone.  
Participants provided informed consent for the procedures which were approved 
by the Murdoch University Human Research Ethics Committee. Two depressed 
participants withdrew from the experiment during the math task and one control 
withdrew because of an adverse reaction to naltrexone (vertigo). Participants received 
$20 for their participation. 
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Procedures 
Design overview. The experiment was carried out in a laboratory maintained at 22 
± 2°C. The participants were randomly assigned to either a naltrexone or placebo 
condition. An identical capsule containing a 50 mg caplet of naltrexone or a sugar pill 
was administered double-blind. This dose of naltrexone blocks the subjective and 
objective effects of intravenous opioid challenge [11, 21], and would be expected to 
block effects of endogenous opioid release. When asked after the experiment whether 
they thought that they had taken naltrexone, participants guessed correctly at a rate no 
greater than chance. In the depressed group, four men and six women took naltrexone, 
and another seven men and seven women took the placebo. In the control group, six men 
and eight women took naltrexone, and another eight men and nine women took the 
placebo. Eighty minutes later, after the naltrexone had been absorbed [21], participants 
completed a cold pressor test and, after a 5-minute interval, began a 25-minute arithmetic 
task. Participants completed a second cold pressor test ten minutes after the arithmetic 
task. Naltrexone has a half-life of approximately four hours [11]. 
Dependent variables. Prior to drug absorption, an hour later and again after the 
math task, participants rated anxiety, discouragement, anger and filler items (confusion, 
sluggishness and liveliness) on separate 100 mm visual analogue scales ranging from 
“not at all” to “extremely”. The participants were instructed to rate how they felt right 
now. Subjects rated their mood using the same scales at intervals of 5-7 minutes during 
the arithmetic task, starting 1.5 minutes into the task. During the cold pressor test 
participants rated pain and unpleasantness at 30-second intervals using two 0-10 point 
verbal rating scales until the pain became intolerable – at which point a final rating was 
made (0 corresponded to ‘no pain’ or ‘not unpleasant at all’ and 10 to ‘pain as bad as it   7 
could get’ or ‘as unpleasant as it could get’). In addition, the intensity and unpleasantness 
of seven painful electric shocks administered during the math task were rated on 100 mm 
visual analogue scales ranging from “no pain” or “not unpleasant at all” to “pain as bad 
as it could get” or “as unpleasant as it could get”.   
Cold pressor test. Participants immersed their non-dominant foot to the top of the 
lateral malleolus in 37°C water for three minutes to standardise foot temperature, then 
placed their foot in 2°C ice-water for as long as they could tolerate or until four minutes 
had elapsed. A small aquarium pump circulated the ice-water to prevent pockets of warm 
water developing around the foot.  
Math task. Addition and subtraction items varied across five levels of difficulty, 
and the difficulty of the problems was adjusted automatically to ensure a 75% failure rate 
across the 25 minutes of the task [20]. At the outset of the task subjects were told that the 
number of shocks that they would receive would depend on their performance. However, 
no such contingency existed and all participants received an identical number of shocks at 
similar stages throughout the task. Each math question appeared in yellow 2 cm high 
numbers in the middle of a black computer screen. To increase the difficulty of the task, 
subjects used their non-dominant hand to type in their answers using the row of numbers 
at the top of a computer keyboard (and not the number-pad). Once a problem was 
completed or time had elapsed for that question, feedback such as ‘CORRECT’ (green), 
‘INCORRECT’ (red) or ‘TOO SLOW’ (purple) appeared on the computer screen. Either 
a pleasant 3-note jingle (correct response) or an aversive loud beep (too slow or incorrect 
response) sounded for one second. 
Electric shocks. Seven 15 mA shocks of 25 milliseconds duration were delivered 
at irregular intervals throughout the math task to prevent subjects from anticipating their   8 
occurrence. Each pulse was delivered by an SD9 Grass Square Pulse stimulator and 
constant current unit via 1 cm
2 silver/silver chloride surface electrodes filled with water-
soluble electrode gel and attached 2 cm apart over the right lateral sural nerve behind the 
lateral malleolus. The skin was slightly abraded with a pumice stone and degreased with 
an alcohol swab to reduce skin impedance below 5 KΩ. The math task was suspended 
after each shock whilst subjects gave pain intensity and unpleasantness ratings. 
 Data analysis 
Mood ratings. Changes in anxiety, discouragement and anger over the course of 
the experiment were investigated in Group (depressed, control) x Drug (natrexone, 
placebo) x Time (before drug administration, 60 minutes after drug administration, five 
times during the math task, and shortly after the math task) analyses of variance. The 
multivariate solution was employed for repeated measures factors with more than two 
levels. Significant effects that included Time were investigated in planned contrasts 
between consecutive time points. 
Cold-induced pain. Tolerance scores derived from the duration of foot immersion 
were log-transformed to reduce the distribution skew created by participants who 
tolerated the cold pressor test for the entire four-minute period. These log-transformed 
scores, and mean ratings of the intensity and unpleasantness of pain, were investigated in 
Group x Drug analyses of variance. The relationship between cold-induced pain, 
depression severity and prior mood was investigated with Pearson’s correlation 
coefficient. Differences in the relationship between the naltrexone and placebo conditions 
were investigated in hierarchical multiple linear regression analyses, calculated separately 
for depressed and non-depressed participants because of substantial differences in mood 
between the two groups. In each regression model, the Drug condition (naltrexone or   9 
placebo) was dummy-coded and entered in the first step. Mood or depression severity 
was also entered in the first step, and the interaction term (the product of Drug and Mood 
or Depression Severity) was entered in the second step. The Drug x Mood/Depression 
Severity interaction tested whether naltrexone altered the relationship between pain 
ratings and mood (as might be expected if stress-evoked opioid release inhibits pain). 
Shock-induced pain. Ratings of the intensity and unpleasantness of shock-induced 
pain (averaged over the seven shocks) were investigated in analyses of variance with 
factors of Group and Drug. The relationship between shock-induced pain and 
mood/depression severity ratings during the math task was investigated with Pearson’s 
correlation coefficient and in hierarchical multiple linear regression analyses, as 
described above. 
  The criterion of statistical significance was p<0.05. Data are reported as the mean 
+ standard error. 
Results 
Mood ratings  
As shown in Figure 1, negative affect was greater in depressed participants than 
controls throughout the experiment [for anxiety, F(1,50) = 6.31, p<0.05; for 
discouragement, F(1,50) = 17.6, p<0.001; for anger, F(1,50) = 10.2, p<0.01].  
Anxiety ratings differed across the course of the experiment [main effect for 
Time, F(7,44) = 16.7, p<0.001]. In particular, anxiety decreased after drug administration 
(p<0.05) but then increased rapidly during the math task (difference between pre-math 
anxiety and first measure during math, p<0.001) (Figure 1A-B). Both in depressed and 
non-depressed participants, ratings decreased during the second half of the task in the 
placebo condition but continued to increase in the naltrexone condition [Time x Drug,   10 
F(7,44) = 2.96, p<0.05] (Figure 1A-B). Investigation of this interaction indicated that 
anxiety decreased in the placebo condition between the third and fourth measurement 
points (approximately 15 minutes into the task) but continued to increase in the 
naltrexone condition [Time (third to fourth measurement point) x Drug F(1,50) = 15.7, 
p<0.001]. Anxiety decreased in all groups after the math task (difference between final 
measure during math and the post-math measure, p<0.001). 
Discouragement and anger also differed across the course of the experiment [for 
discouragement, F(7,44) = 12.9, p<0.001, for anger, F(7,44) = 8.54, p<0.001] (Figure 1C-
F). In particular, both discouragement and anger increased rapidly during the math task 
(difference between pre-math anxiety and first measure during math, p<0.001) and 
remained high until after the task had finished (difference between the final measure 
during math and the post-math measure, p<0.05 for discouragement and p<0.01 for 
anger). Naltrexone did not influence ratings of discouragement or anger in depressed or 
non-depressed participants. 
Cold-induced pain 
  Both before and after the math task, approximately 40% of participants tolerated 
the cold pressor test for the entire four-minute period. These participants were spread 
fairly evenly across the naltrexone and placebo conditions in the depressed and control 
groups (Table 2). The cold pressor test was rated as moderately to intensely painful and 
unpleasant: intensity ratings averaged 7.5 + 0.3 and unpleasantness ratings averaged 7.8 + 
0.3 on 0-10 scales. In the group as a whole, neither pain tolerance nor pain ratings 
differed between the naltrexone and placebo conditions, or between depressed 
participants and controls, before or after the math task (none of the F ratios that included 
these effects were statistically significant).    11 
  In depressed participants who took naltrexone, depression severity and negative 
affect before the first cold pressor test was greatest in those who subsequently reported 
most cold-induced pain (Table 3). However, this relationship moved in the opposite 
direction in depressed patients who took the placebo. Hierarchical multiple linear 
regression analyses confirmed that naltrexone reversed the relationship between negative 
affect/depression severity and pain in depressed participants during the first cold pressor 
test (Table 3). Naltrexone also reversed the association between depression severity and 
pain unpleasantness after the math task (Table 4), but did not alter the relationship 
between pain and anxiety, discouragement or anger. 
Naltrexone did not influence the association between negative affect and pain in 
controls, either before or after the math task (Tables 3 and 4). Curiously, however, 
naltrexone unmasked a negative association between pain ratings and depression severity 
scores in controls (Tables 3 and 4). 
Shock-induced pain  
  Electric shocks administered during the math task were rated as moderately 
painful. Neither ratings of pain intensity nor unpleasantness differed significantly 
between depressed participants and controls, or between the naltrexone and placebo 
conditions.  
In the naltrexone condition, the intensity and unpleasantness of shock-induced 
pain was greatest in subjects who reported most negative affect (Table 5). In depressed 
participants, the relationship between pain ratings and negative affect was stronger in the 
naltrexone condition than the placebo condition (Table 5). Pain ratings were unrelated to 
depression severity scores in the MDD group, but were negatively associated with 
depression severity scores in controls administered naltrexone (Table 5).   12 
Discussion 
  The main finding of this study was that the µ-opioid receptor antagonist 
naltrexone strengthened the relationship between negative affect and pain, particularly in 
the MDD group. This finding suggests that psychological stress triggered the release of 
endogenous opioid peptides in the most distressed participants, and that µ-opioid activity 
masked a direct linear relationship between negative affect and pain. 
Stress-induced analgesia  
  Opioid analgesia has been identified in a diverse range of animal models, 
characterized by lack of control over aversive stimuli such as cold-water immersion, 
electric shocks, and centrifugal rotation [1, 41]. In human research, µ-opioid receptor 
blockade antagonized stress-induced analgesia evoked by noxious electric shocks [47, 
48], immersion of a limb in ice-water [28, 40], the perception of failure on a difficult 
cognitive task [2, 3, 20], a combat video shown to Vietnam veterans with post-traumatic 
stress disorder [38], and a first-time parachute jump [27]. Effects of µ-opioid receptor 
blockade on experimental pain are more variable [16, 23, 40], possibly because of 
individual differences in sensitivity to or release of opioid peptides. For example, 
naloxone augments shock-induced pain and cortical evoked potentials in pain-tolerant 
people, but inhibits pain and cortical evoked potentials in pain-sensitive people [10]. We 
recently reported that µ-opioid receptor blockade facilitated pain induced by repeated 
immersions of a hand in ice-water in pain-tolerant subjects, but had no effect on pain 
induced by the first, less stressful, immersion [40]. In the present study, naltrexone failed 
to augment pain induced by electric shocks or single ice-water immersions in the group 
as a whole. Thus, psychological stress may trigger endogenous opioid release more 
readily than transient painful stimulation.   13 
We previously investigated the effect of naltrexone on cold-induced pain in non-
depressed people before and after stressful mental arithmetic [20]. To heighten negative 
affect, participants received noxious electric shocks at irregular intervals throughout the 
math task. Within the naltrexone condition, cold-induced pain and unpleasantness 
increased after the math task in line with ratings of discouragement. This relationship was 
absent in the placebo condition, implying that opioid release inhibited cold-induced pain 
in the most discouraged cases. In the present study, a similar protocol was employed to 
investigate effects of MDD on stress-induced opioid analgesia. In contrast to our previous 
report [20], naltrexone unmasked a positive association between negative affect and cold-
induced pain before the math task in depressed participants; moreover, in the naltrexone 
condition, both cold-induced pain and unpleasantness increased in line with depression 
severity. These relationships were absent in the placebo condition, implying that 
psychological distress mobilized the opioid system in MDD. Thus, our findings suggest 
that chronic stress-induced activation of the opioid system inhibited cold-induced pain in 
severely depressed participants. In emotionally-neutral states, the bioavailability of µ-
opioid receptors in the posterior thalamus is lower in women with MDD than in non-
depressed controls, consistent with chronic over-activity of the opioid system in MDD 
[30]. Bioavailability of µ-opioid receptors decreases in this part of the brain during 
painful stimulation [7, 50], presumably due to pain-induced release of endogenous 
opioids.  
During stressful mental arithmetic, naltrexone strengthened an association 
between negative affect and shock-induced pain, particularly in the MDD group. Opioid 
activity increases in the subamygdalar-left inferior temporal cortex of depressed patients 
during sustained sadness, and increases in the anterior cingulate region of patients who   14 
fail to respond to antidepressant medication [30]. Thus, the µ-opioid system may be over-
active in severely affected MDD patients, not only at rest but also during emotional 
challenges. 
After the math task, naltrexone strengthened an association between pain 
unpleasantness and severity of depression in the MDD group, suggesting that opioid 
analgesia was greatest in the most severely depressed cases. Surprisingly, however, 
naltrexone-hyperalgesia was unrelated to the intensity of negative affect. The reason for 
this discrepancy is unclear, but may be due to the development of non-opioid analgesia 
during stressful mental arithmetic. Non-opioid analgesic mechanisms appear to be active 
during stressful experiences until the outcome is no longer easily controlled; this loss of 
control then augments endogenous µ-opioid neurotransmission [2, 29].  
Curiously, naltrexone-hyperalgesia was greatest in controls with the lowest 
depression severity scores (contrary to participants with MDD). Opioid activity decreases 
in the rostral anterior cingulate region of non-depressed controls during sustained 
sadness, in association with heightened negative affect [30]. Thus, in the absence of 
depression, sadness may be associated with a reduction in normal, background opioid 
release in a region of the brain that regulates affective responses. The present findings 
suggest that naltrexone blocked an analgesic effect of tonic opioid release in non-
depressed controls with few or no depressive symptoms. Importantly, naltrexone had 
little influence on the mood-pain relationship in this group, implying that heightened 
tonic µ-opioid neurotransmission was associated more closely with lack of depressive 
symptoms than with negative affect.  
Effect of naltrexone on mood   15 
Negative affect was greater in depressed than non-depressed participants 
throughout the study, as was the unpleasantness of shock-induced pain. Although 
increments in negative affect were similar in both groups during the math task, naltrexone 
blocked decreases in anxiety toward the end of the task. Thus, stress-induced opioid 
release apparently suppressed anxiety both in MDD participants and non-depressed 
controls. Functional neuroimaging studies suggest that the endogenous opioid system has 
an anxiolytic role in regions of the temporal lobe that project to the amygdala [35], and 
suppresses affective states such as sadness [30, 51].  
Negative affect during stressful mental arithmetic increased in line with the 
intensity and unpleasantness of shock-induced pain, particularly in the naltrexone 
condition. The positive association between negative affect and pain could reflect several 
mechanisms, including hypervigilance to pain, muscular reactivity, autonomic arousal, or 
misattribution of arousal in distressed participants [26]. Alternatively, the pain provoked 
by the electric shocks may have enhanced negative affect. Animal studies have 
implicated activation of the limbic system, a deficit in central serotonergic 
neurotransmission, dysfunction of the hypothalamic-pituitary-adrenal axis, and 
hypofunction of supraspinal µ-opioid receptors in various models of stress-induced 
hyperalgesia [25]. Whatever the mechanism, the present findings indicate that 
endogenous opioids masked the relationship between negative affect and pain, 
particularly in the MDD group. 
Limitations 
The rigorous inclusion and exclusion criteria used to select MDD participants and 
controls places limits on how far the present findings might generalize to their respective 
populations. Many potential recruits with MDD were excluded because they took drugs   16 
that might affect µ-opioid neurotransmission (antidepressants, nicotine, psychotropic 
agents or pain medication). Controls had to be free of psychiatric illness, both personally 
and within their immediate family. The use of these selection criteria may account for 
discrepancies between the present findings and those reported previously. For example, 
we previously found evidence of opioid analgesia in discouraged participants after 
stressful mental arithmetic [20]. In contrast, opioid analgesia after the math task was 
unrelated to discouragement in the present study, perhaps due to a restricted range of 
affect within homogenous groups of participants.  
In a second important discrepancy, naltrexone enhanced anxiety during the math 
task in the present study. The present sample of participants was recruited from the 
community, and might have felt more threatened by task demands (thereby activating the 
opioid system more strongly to counteract anxiety) than the previous university-based 
sample [20].  
We asked participants to rate discouragement rather than sadness because loss of 
control (akin to a sense of helplessness or hopelessness) appears to be important both in 
depression [24] and in stress-induced opioid analgesia [2, 3]. In retrospect, however, it 
would have been interesting to measure sadness in addition to discouragement because 
melancholia is a major feature of depression.  
Finally, opioid analgesia was greater in women than men in our previous study 
[20], possibly because women became more discouraged than men during the math task. 
The sample recruited for the present study was not large enough to investigate sex 
differences in opioid analgesia within the MDD population. However, sex differences 
may be important because women are more sensitive to pain than men [17, 46] due, in 
part, to modulatory effects of oestrogen on subcortical opioid neurotransmission [43].   17 
Conclusions 
Lautenbacher et al. [33] reported that µ-opioid receptor blockade had no 
consistent effect on heat pain thresholds in depressed patients. Similarly, in the present 
study, naltrexone had no consistent effect on pain intensity in the MDD group as a whole, 
either before, during or after psychological stress. Nevertheless, naltrexone strengthened 
the relationship between negative affect and cold- and shock-induced pain, particularly in 
the MDD group, consistent with heightened µ-opioid neurotransmission and opioid 
analgesia in the most distressed cases. These findings support the view that the opioid 
system, which forms an interface between physical and emotional stress regulation [39], 
is chronically over-active in the most severe cases of MDD [30]. Further studies are 
required to determine whether this over-activity promotes opioid tolerance, a factor 
implicated in the development of chronic pain [9].  
Our findings also suggest that high tonic µ-opioid neurotransmission inhibited 
pain in controls with few or no symptoms of depression. If so, high tonic levels of opioid 
activity might decrease vulnerability to depressive symptomatology.  
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Table 1: Anxiety, depression and stress in depressed participants and controls  
  Depressed (N = 24)  Controls (N = 31)   
  Mean ± SD  Mean ± SD  t-test 
Age (years)  35.3 ± 12.0  36.3 ± 13.2  .29 
STAI       
State anxiety  56.9 ± 13.3  31.6 ± 8.3  8.77* 
Trait anxiety  58.2 ± 10.9  31.6 ± 8.3  10.30* 
DASS       
Depression scale  23.7 ± 10.9  3.0 ± 4.8  9.49* 
Anxiety scale  14.0 ± 10.8  1.8 ± 2.2  6.11* 
Stress scale  25.2 ± 10.7  6.5 ± 5.4  8.40* 
BDI-II       
Depression  27.6 ± 12.6  3.6 ± 3.6  10.08* 
Note. *p<.001 
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Table 2: Number of participants who tolerated the cold pressor test for the full four 
minutes  
  Depressed   Controls  
Before math     
Placebo condition  5/14 (38%)  7/17 (41%) 
Naltrexone condition  3/10 (30%)  6/14 (43%) 
After math     
Placebo condition  6/14 (43%)  8/17 (47%) 
Naltrexone condition  2/10 (20%)  6/14 (43%) 
Note: the proportion of participants who tolerated the cold pressor test for the full four 
minutes did not differ significantly between the placebo or naltrexone conditions in 
depressed participants or controls, either before or after the math task.   26 
Table 3: Association between mood and cold-induced pain before the math task 
  Major Depressive Disorder   Controls 
  Correlations  F(1,20)^  Correlations  F(1,27)^ 
  Placebo  
(N = 14) 
Naltrexone  
(N = 10) 
  Placebo  
(N = 17) 
Naltrexone  
(N = 14) 
 
Pain Intensity             
Depression severity 
#  -.41  .80***  6.02*  .42  -.54*  6.59* 
Anxiety  -.38  .67*  4.64*  .06  -.18  .32 
Discouragement  -.40  .63*  4.69*  .06  -.09  .13 
Anger  -.33  .55  3.01  .06  .02  .03 
Unpleasantness             
Depression severity 
#  -.45  .63*  5.73*  .37  -.44  4.80* 
Anxiety  -.39  .61  4.78*  .04  -.13  .17 
Discouragement  -.40  .57  4.61*  .04  -.04  .05 
Anger  -.34  .44  2.79  .04  -.01  .02 
Pain tolerance             
Depression severity 
#  .00  -.49  1.37  -.17  .23  1.21 
Anxiety  -.22  -.46  .15  -.03  .28  1.09 
Discouragement  -.21  -.60  .55  .31  -.08  .90 
Anger  -.29  -.56  .34  .31  -.18  1.89 
*p<.05; *** p<.001 
# Scores on the Beck Depression Index were used as an index of depression severity. These scores ranged between 4 and 49 in the MDD group and 
between 0 and 13 in controls. 
^ The Drug x Depression Severity/negative affect interaction in hierarchical multiple linear regression analyses, which tests whether correlations differ 
between the placebo and naltrexone conditions.   27 
Table 4: Association between mood and cold-induced pain after the math task 
  Major Depressive Disorder   Controls 
  Correlations  F(1,20)^  Correlations  F(1,27)^ 
  Placebo  
(N = 14) 
Naltrexone  
(N = 10) 
  Placebo  
(N = 17) 
Naltrexone  
(N = 14) 
 
Pain Intensity             
Depression severity 
#  -.41  .45  3.38  .36  -.55*  6.48* 
Anxiety  -.07  .11  .12  .04  .38  .83 
Discouragement  -.02  .28  .19  -.08  .34  1.15 
Anger  .06  .41  .12  -.16  .25  1.15 
Unpleasantness             
Depression severity 
#  -.46  .50  4.39*  .37  -.44  4.82* 
Anxiety  -.06  .22  ,22  .17  .35  .20 
Discouragement  -.05  .43  .58  .10  .31  .23 
Anger  -.03  .49  .53  .02  .32  .47 
Pain tolerance             
Depression severity 
#  .04  -.41  1.17  -.28  .31  2.50 
Anxiety  -.36  -.41  .02  -.21  -.09  .03 
Discouragement  -.28  -.54  .80  -.16  -.28  .37 
Anger  -.18  -.72*  1.68  -.11  -.01  .00 
*p<.05 
# Scores on the Beck Depression Index were used as an index of depression severity.  
^ The Drug x Depression Severity/negative affect interaction in hierarchical multiple linear regression analyses, which tests whether correlations differ 
between the placebo and naltrexone conditions.   28 
Table 5: Association between shock-induced pain and mood during the math task 
  Major Depressive Disorder   Controls 
  Correlations  F(1,20)^  Correlations  F(1,27)^ 
  Placebo  
(N = 14) 
Naltrexone  
(N = 10) 
  Placebo  
(N = 17) 
Naltrexone  
(N = 14) 
 
Pain Intensity             
Depression severity 
#  -.27  .09  .52  .21  -.54*  5.88* 
Anxiety  .10           .80**  5.98*  .46         .79***  2.43 
Discouragement  -.03  .78*  7.72*  .14      .64*  4.14 
Anger  .03  .63  2.78  .34  .38  .43 
Unpleasantness             
Depression severity 
#  -.18  -.05  .03  .02  -.45  2.35 
Anxiety  .18  .84**  7.74*    .58*    .52  .00 
Discouragement  .13  .90***  12.6**  .30      .65*  2.40 
Anger  .15  .78*  4.80*  .39  .07  .36 
*p<.05; **p<.01; ***p <.001 
# Scores on the Beck Depression Index were used as an index of depression severity.  
^ The Drug x Depression Severity/negative affect interaction in hierarchical multiple linear regression analyses, which tests whether correlations differ 
between the placebo and naltrexone conditions. 
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Figure legend 
Figure 1. Change in mood ratings (± S.E.) over the course of the experiment in the naltrexone 
condition (filled circles) and placebo condition (open circles).   30 
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